Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SERUM CONCENTRATIONS OF FLUVOXAMINE AND CLINICAL EFFECTS - A PROSPECTIVE OPEN CLINICAL-TRIAL
Autore:
HARTTER S; WETZEL H; HAMMES E; TORKZADEH M; HIEMKE C;
Indirizzi:
UNIV MAINZ,ABT PSYCHIAT,UNTERE ZAHLBACHER STR 8 D-55131 MAINZ GERMANY UNIV MAINZ,ABT PSYCHIAT D-55131 MAINZ GERMANY
Titolo Testata:
Pharmacopsychiatry
fascicolo: 5, volume: 31, anno: 1998,
pagine: 199 - 200
SICI:
0176-3679(1998)31:5<199:SCOFAC>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLASMA; DEPRESSION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
11
Recensione:
Indirizzi per estratti:
Citazione:
S. Hartter et al., "SERUM CONCENTRATIONS OF FLUVOXAMINE AND CLINICAL EFFECTS - A PROSPECTIVE OPEN CLINICAL-TRIAL", Pharmacopsychiatry, 31(5), 1998, pp. 199-200

Abstract

This pilot study examined prospectively blood serum concentrations offluvoxamine, side effects and therapeutic response after a fixed dosage of 100 mg fluvoxamine/day for 14 days. Twenty male and female patients who met the DSM-IV criteria of a major depression received 50 mg fluvoxamine b.i.d. for two weeks. On days 7 and 14 side effects and therapeutic response were registered and serum concentrations of fluvoxamine were determined. A Receiver Operating Characteristic (ROC) curve was constructed to determine a possible relationship between serum concentrations and clinical effects. The serum concentrations of fluvoxamine were highly variable, even when dosages were corrected for body weight, ranging between 23 to 227 mu g/l. No relationship between serum concentrations and side effects was detectable. On the other hand, ROC analysis, conducted on day 14, revealed a significant upper concentration threshold of 85 mu g/l (p < 0.01) with no responder above this threshold. The results of this pilot study should be regarded as a hint at the possible therapeutic benefits of lower fluvoxamine serum concentrations by means of lower fluvoxamine dosages. Furthermore, this indicates for the first time that therapeutic drug monitoring might be useful for patients under antidepressant therapy with fluvoxamine.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 02:18:36